Real-world analysis demonstrates increased treatment persistence in individuals prescribed GLP-1RA, suggesting improved management strategies.
This real-world analysis of high-potency, weight loss-indicated GLP-1RA products among individuals without diabetes found that 1-year treatment persistence has nearly doubled from 33.2% in 2021 to 60.9% in 1H 2024. GLP-1RA product shortage resolution may have improved persistence rates. Other potential influencing factors include improved GLP-1RA dose escalation and side effect management, as well as weight loss lifestyle management programs. Additional research is needed to understand treatment discontinuation reasons and long-term GLP-1RA cost-effectiveness.
No takes yet. Share an insight, caveat, or question.
Marshall et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: